Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. — ATLANT

Neuroendocrine Tumours Clinical Trial

Official title:
Efficacy and Safety of Lanreotide ATG 120 mg in Combination With Temozolomide in Subjects With Progressive Well Differentiated Thoracic Neuroendocrine Tumors. A Phase II, Multicentre, Single Arm, Open-label Trial.

Status Completed

Clinical Trial Summary

The purpose of the protocol is to evaluate the efficacy and safety of Lanreotide ATG 120 mg in combination with Temozolomide in subjects with unresectable advanced neuroendocrine tumours of the lung or thymus as Disease Control Rate at 9 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02698410
Study type	Interventional
Source	Ipsen
Contact
Status	Completed
Phase	Phase 2
Start date	July 2016
Completion date	June 18, 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00323076` - [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours	Phase 1/Phase 2
Completed	`NCT02075606` - Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients	Phase 4
Completed	`NCT00326469` - Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours	Phase 2
Terminated	`NCT02788578` - A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
Completed	`NCT01840449` - Somatuline Predictive Factors in Acromegaly and NET
Active, not recruiting	`NCT02923934` - A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers	Phase 2
Completed	`NCT01673906` - 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours	Phase 2
Active, not recruiting	`NCT04579679` - Open-Label Surufatinib in European Patients With NET	Phase 2